Back to Newsroom

StemCells, Inc. Reports Top Line Results for Its Phase I/II Study in Dry Age Related Macular Degeneration

NEWARK, Calif., June 26, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(NASDAQ:STEM), a leading stem cell company developing novel cell-based therapeutics for treating diseases and disorders of the central nervous system, announced today that Dr. Stephen Huhn, its Vice President of Clinical Research and Chief Medical Officer, presented an overview of the Company’s clinical translation efforts to date, including a summary of the safety and preliminary efficacy data from the Company’s Phase I/II study investigating its proprietary HuCNS-SC® cells (purified human neural stem cells) as a potential therapy for geographic atrophy, the most advanced form of dry age related macular degeneration (AMD). The summary was presented Friday, June 26, at 4:00 p.m. CEST, at the 2015 Annual Meeting of theInternational Society for Stem Cell Research (ISSCR) being held in Stockholm, Sweden.

Click here to read more